A new sensitive assay for measuring volatile sulphur compounds in human breath by Tenax trapping and gas chromatography and its application in liver cirrhosis

Tangerman, A.; Meuwese-Arends, Maria T.; Tongeren, J. H. M. Van

doi:10.1016/0009-8981(83)90263-2

Cited by 82 publications

(73 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Volatile sulphur compounds in the breath have previously been assessed in the context of oral malodour [28], occupational exposure [29], congenital enzyme deficiency [30] and liver cirrhosis [31]. While elevation of DMS was found in all of these conditions, a markedly decreased breath output was measured in the CF population.…”

Section: Discussionmentioning

confidence: 99%

Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis

Barker

Hengst²,

Schmid³

et al. 2006

Eur Respir J

160

124

View full text Add to dashboard Cite

Inflammatory mediators in the exhaled breath are receiving growing medical interest as noninvasive disease markers. Volatile organic compounds have been investigated in this context, but clinical information and methodological standards are limited.The levels of ethane, propane, n-pentane, methanol, ethanol, 2-propanol, acetone, isoprene, benzene, toluene, dimethyl sulphide (DMS) and limonene were measured in repeated breath samples from 20 cystic fibrosis patients and 20 healthy controls (aged 8-29 yrs). Three endexhaled and one ambient air sample were collected per person and analysed on a customised gas chromatography system. Intra-subject coefficients of variation ranged between 9 and 34%, and hydrocarbon breath levels were influenced by their inspired concentrations. The alveolar gradient for pentane was higher in cystic fibrosis patients than in healthy controls (0.36 versus 0.21 ppb) and inversely proportional to forced expiratory volume in one second; highest values were observed in patients with pulmonary exacerbations (0.73 versus 0.24 ppb). Cystic fibrosis patients also exhibited a lower output of DMS (3.9 versus 7.6 ppb). Group differences were not significant for ethane and the remaining substances.It was concluded that chemical breath analysis for volatile organic compounds is feasible and may hold potential for the noninvasive diagnosis and follow-up of inflammatory processes in cystic fibrosis lung disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis

Barker

Hengst²,

Schmid³

et al. 2006

Eur Respir J

160

124

View full text Add to dashboard Cite

show abstract

“…The minimal quantitation level was 0.100 pg/mL; the intraassay coefficient of variability was 5.7%. Breath dimethylsulfide was assayed by gas chromatography as previously described (26). Dimethylsulfide in urine was measured in the same way as previously reported for blood (27).…”

mentioning

confidence: 99%

“…Breath dimethylsulfide was assayed by gas chromatography as previously described (26). Dimethylsulfide in urine was measured in the same way as previously reported for blood (27). In short, 2 mL of fresh urine was injected into a closed evacuated 15-mL glass vial.…”

mentioning

confidence: 99%

Intravenous Cysteamine Therapy for Nephropathic Cystinosis

et al. 1995

Self Cite

View full text Add to dashboard Cite

“…Measured volumes of breath (100 and 250 ml) were collected in Tenax (Chrompack, Middleburg, The Netherlands) tubes, and dimethylsulfide was analyzed as previously described [Tangerman et al, 1983]. Urinary methionine TA metabolites were determined as the sum of the methanethiol released into the gas phase at pH 12.5-13.0 [Blom et al, 1989].…”

Section: Breath Dimethylsulfide and Urinary Methionine Transaminationmentioning

confidence: 99%

Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/III

et al. 1998

Self Cite

View full text Add to dashboard Cite

Two isozymes of mammalian methionine adenosyltransferase, MAT I and MAT III, are expressed solely in adult liver. They are, respectively, tetramers and dimers of a single subunit encoded by the gene MAT1A. A third isozyme, MAT II, contains a catalytic subunit encoded by a separate gene, MAT2A, and is expressed in a variety of tissues, including (to a slight extent) adult liver. Based on a recent finding that 2 children with isolated hypermethioninemia and brain demyelination were homozygous for MAT1A mutations predicted to produce severely truncated proteins, and devoid of activity when expressed, it was concluded that complete lack of MAT I/III activity may be associated with neurological symptoms and demyelination. We now report that a 43-year-old man with persistent isolated hypermethioninemia, previously demonstrated to have deficient MAT activity in his liver, has normal brain myelination on MRI and normal neurological function, despite being homozygous for a 539 TG insertion in exon V of MAT1A, so that the gene is predicted to encode a protein of only 184 rather than the normal 395 amino acids. This patient's exon V mutation was demonstrated by SSCP analysis and verified by sequencing. Both parents are heterozygous for the same insertion. This suggests that MAT1A mutations producing severely truncated proteins do not necessarily produce brain demyelination. This finding has relevance to a previously reported 4-year-old girl who was also homozygous for the 539insTG mutation. Finally, our patient's 7% residual hepatic MAT activity, measured at 1 mM methionine, may reflect the hepatic activity of the more ubiquitous enzyme form, MAT II.

show abstract

A new sensitive assay for measuring volatile sulphur compounds in human breath by Tenax trapping and gas chromatography and its application in liver cirrhosis

Cited by 82 publications

References 8 publications

Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis

Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis

Intravenous Cysteamine Therapy for Nephropathic Cystinosis

Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/III

Contact Info

Product

Resources

About